FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.96 USD
0 (0%)
Earnings
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
2025-03-25
2.93M
-0.31
-0.23
34.78%
2024-11-12
13.53M
-0.18
-0.14
28.57%
2024-08-07
8.97M
-0.29
-0.35
-17.14%
2024-05-08
12.44M
-0.81
-0.72
12.50%
2024-03-05
10.68M
-1.11
-1.22
-9.02%
2023-11-14
12.03M
-1
-1.31
-23.66%
2023-08-14
36.05M
-0.83
-1.04
-20.19%
2023-05-03
41.62M
-1.08
-1.19
-9.24%
2023-03-16
56.18M
-0.6
-1.53
-60.78%
2022-11-07
13.41M
-1.76
-1.74
1.15%
2022-08-10
13.48M
-2.02
-2.08
-2.88%
2022-05-12
8.43M
-3.2
-1.73
84.97%
2022-03-22
16.03M
-2.55
-2.45
4.08%
2021-12-01
19.26M
-2.62
-2.71
-3.32%
2021-08-12
7.33M
-3.61
0
-
2021-05-11
9.9M
-3.3
0
-
2021-03-31
11.9M
-3.74
0
-
2020-09-30
18.43M
-3.1
0
-
2020-06-30
109.89M
0.62
0
-
2020-03-31
109.89M
0.62
0
-
